Metformin Prevents Tumor Cell Growth and Invasion of Human Hormone Receptor-Positive Breast Cancer (HR+ BC) Cells via FOXA1 Inhibition
Authors:
- Christine SongCSChristine Song
- Dawa JungDJDawa Jung
- Ayse Tuba KendiAKAyse Tuba Kendi
- Jin Kyung RhoJRJin Kyung Rho
- Eun-Joo KimEKEun-Joo Kim
- Ian HornIHIan Horn
- Geoffry L. CurranGCGeoffry L. Curran
- Sujala GhattamaneniSGSujala Ghattamaneni
- Ji Yeon ShimJSJi Yeon Shim
- Pil Soo KangPKPil Soo Kang
- Daehun KangDKDaehun Kang
- Jay B. ThakkarJTJay B. Thakkar
Open Access
- 8 July 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7494
Abstract
Women with type 2 diabetes (T2D) have a higher risk of being diagnosed with breast cancer and have worse survival than non-diabetic women if they do develop breast cancer. However, more research is needed to elucidate the biological underpinnings of these relationships. Here, we found that forkhead box A1 (FOXA1), a forkhead family transcription factor, and metformin (1,1-dimethylbiguanide hydrochloride), a medication used to treat T2D, may impact hormone-receptor-positive (HR+) breast cancer (BC) tumor cell growth and metastasis. Indeed, fourteen diabetes-associated genes are highly expressed in only three HR+ breast cancer cell lines but not the other subtypes utilizing a 53,805 gene database obtained from NCBI GEO. Among the diabetes-related genes, FOXA1, MTA3, PAK4, FGFR3, and KIF22 were highly expressed in HR+ breast cancer from 4032 breast cancer patient tissue samples using the Breast Cancer Gene Expression Omnibus. Notably, elevated FOXA1 expression correlated with poorer overall survival in patients with estrogen-receptor-positive/progesterone-receptor-positive (ER+/PR+) breast cancer. Furthermore, experiments demonstrated that loss of the FOXA1 gene inhibited tumor proliferation and invasion in vitro using MCF-7 and T47D HR+ breast cancer cell lines. Metformin, an anti-diabetic medication, significantly suppressed tumor cell growth in MCF-7 cells. Additionally, either metformin treatment or FOXA1 gene deletion enhanced tamoxifen-induced tumor growth inhibition in HR+ breast cancer cell lines within an ex vivo three-dimensional (3D) organoid model. Therefore, the diabetes-related medicine metformin and FOXA1 gene inhibition might be a new treatment for patients with HR+ breast cancer when combined with tamoxifen, an endocrine therapy.Keywords
This publication has 57 references indexed in Scilit:
- ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitorBreast Cancer, 2023
- Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast CancerJAMA, 2022
- Organoids in cancer research: a review for pathologist‐scientistsThe Journal of Pathology, 2021
- Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC)Breast Cancer, 2021
- Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast CancerDrugs, 2020
- Breast Cancer TreatmentJAMA, 2019
- Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stageBreast Cancer Research and Treatment, 2014
- FOXA1 is an independent prognostic marker for ER-positive breast cancerBreast Cancer Research and Treatment, 2011
- The -822G/A polymorphism in the promoter region of the MAP4K5 gene is associated with reduced risk of type 2 diabetes in Chinese Hans from ShanghaiJournal of Human Genetics, 2006
- AMP‐activated protein kinase: the energy charge hypothesis revisitedBioEssays, 2001